Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Declines By 29.3%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 12,975 shares, a decrease of 29.3% from the February 12th total of 18,363 shares. Based on an average daily volume of 4,828 shares, the days-to-cover ratio is presently 2.7 days. Currently, 1.0% of the shares of the company are sold short. Currently, 1.0% of the shares of the company are sold short. Based on an average daily volume of 4,828 shares, the days-to-cover ratio is presently 2.7 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Sonoma Pharmaceuticals Price Performance

SNOA remained flat at $2.45 on Friday. The company had a trading volume of 2,483 shares, compared to its average volume of 10,624. The business has a 50 day moving average of $3.06 and a two-hundred day moving average of $3.58. The company has a market cap of $4.24 million, a price-to-earnings ratio of -1.20 and a beta of 1.66. Sonoma Pharmaceuticals has a 1 year low of $1.75 and a 1 year high of $6.92.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings data on Tuesday, February 10th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). Sonoma Pharmaceuticals had a negative return on equity of 42.56% and a negative net margin of 19.04%.The firm had revenue of $4.35 million during the quarter, compared to the consensus estimate of $5.47 million. On average, research analysts forecast that Sonoma Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of SNOA. McKinley Carter Wealth Services Inc. acquired a new position in shares of Sonoma Pharmaceuticals in the 4th quarter valued at $41,000. Heron Bay Capital Management acquired a new stake in shares of Sonoma Pharmaceuticals during the 2nd quarter valued at about $96,000. Finally, DRW Securities LLC increased its stake in Sonoma Pharmaceuticals by 257.2% in the fourth quarter. DRW Securities LLC now owns 60,977 shares of the company’s stock valued at $222,000 after acquiring an additional 43,907 shares during the period. Institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.